Clinical data | |
---|---|
Trade names | Betapace, Sorine, Sotylize, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693010 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Beta blocker |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90–100%[3] |
Metabolism | Not metabolized[3] |
Elimination half-life | 12 hours[3] |
Excretion | Kidney Mammary gland (In lactating individuals)[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H20N2O3S |
Molar mass | 272.36 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Sotalol, sold under the brand name Betapace among others, is a medication used to treat and prevent abnormal heart rhythms.[1] Evidence does not support a decreased risk of death with long term use.[1] It is taken by mouth or given by injection into a vein.[1]
Common side effects include a slow heart rate, chest pain, low blood pressure, feeling tired, dizziness, shortness of breath, problems seeing, vomiting, and swelling.[1] Other serious side effects may include QT prolongation, heart failure, or bronchospasm.[4] Sotalol is a non-selective β-adrenergic receptor blocker which has both class II and class III antiarrhythmic properties.[1]
Sotalol was first described in 1964 and came into medical use in 1974.[5] It is available as a generic medication.[4] In 2020, it was the 296th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[6][7]
fda2009
was invoked but never defined (see the help page).